Firebrick Pharma Limited (AU:FRE) has released an update.
Firebrick Pharma Limited reported a significant reduction in losses and a dramatic increase in revenues for the financial year ending June 30, 2024, compared to the previous year. The company saw an 82.71% decrease in losses and a 1,400% increase in revenues, although it still did not declare any dividends. Additionally, the company expanded its control by acquiring two subsidiaries, Firebrick Pharma Inc. and Nasodine LLC, within the reporting period.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.
